Clinical Research Studies

We are looking to enroll patients with high concentrations of potassium ('hyperkalemia') and chronic kidney disease. The purpose of this study is to see if a drug, patiromer, can keep blood potassium levels in the normal range in people with chronic kidney disease and mild hyperkalemia (high blood potassium levels) who are transitioned to a plant rich diet that includes high potassium foods. We will also be looking at the effects of a plant rich diet on digestive symptoms, mineral imbalances, inflammation, impaired glucose control, high blood pressure and abnormal blood lipids. Relypsa, Inc. called Veltassa® (or patiromer) was approved by the Food and Drug Administration (FDA) in 2015 for management of hyperkalemia in people with chronic kidney disease. Patriomer has been shown to help lower blood potassium concentrations by binding to potassium in the digestive tract, causing it to be excreted with the medication in feces (stool).